Diagnostics
Posted on: 11/01/2009
Statins, Thiazide Diuretics, and Non-Steroidal Anti-Inflammatory Drugs Lower PSA (Nov-Dec 2010)
PCA3 Urine Test: An Update (Sept-Oct 2010)
PCA3 Urine Test: An Affirmation... and a Modest Retraction (January-February 2010)
Urine - The Next Frontier In Prostate Cancer Diagnosis? (Sept-Oct 2009)
Adding the PC3 test is helpful in the diagnosis of Prostate Cancer (July-Aug 2009)
Two New On-Line Calculators And An Up-Date Of An Older Standard (November 2008)
The Pca3 Urine Test - Increasing Applications (November 2008)
Skeletal Scintigraphy With 18F Sodium Fluoride Positron Emission Tomography (18F-fluoride PET) Offers Greater Overall Accuracy Than 99mTechnetium-MDP for Prostate Cancer Patients (May 2008)
PSA "Bounce" Following Permanent Seed Brachytherapy - A Challenge To Identify And A Cause Of Anxiety For Patients. (January 2008)
Partin Tables Updated (January 2008)
"Magnetic Resonance Imaging of the Axial Skeleton for Detecting Bone Metastases in Patients with High-Risk Prostate Cancer: Diagnostic and Cost-Effectiveness and Comparison With Current Detection Strategies" - JCO August 1, 2007 (January 2008)
Gleason Score Upgrading From Biopsy To Prostatectomy Specimen (January 2008)
PCA3 Molecular Urine Assay for Prostate Cancer in Men Undergoing Repeat Biopsy (May 2007)
Evaluation of Prostascint Scan (May 2007)
Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride [0.5 mg/d] (October 2006)
Defining Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy: A Proposal for a Standardized Definition (October 2006)
National Comprehensive Cancer Network (Nccn) Establishes 2006 Guidelines For Early Detection Of Prostate Cancer (October 2006)
Modified PSA Guidelines For Bone Scanning (October 2006)
UPM3 - A diagnostic urine test with greater accuracy for cancer detection than PSA (April 2006)
Percentage of Positive Biopsy Cores: Riddle - “When is the risk of a Gleason 4 + 3, not that of a “4 + 3”? Answer: When less than 50% of the cores show cancer. (April 2006)
The Importance of Percentage of Gleason Grades 4 Plus 5 in Predicting Biochemical Recurrence in Prostate Cancer (June 2005)
The Utility of Bone Scans in Recurrent Prostate Cancer (June 2005)
A Revisit: Strategy For Re-Biopsy After An Initial Diagnosis Of Isolated HGPIN (January 2005)
"High Grade Prostatic Intraepithelial Neoplasia Is A Disease" (January 2005)
The Prostate Specific Antigen Has Become Less Informative Over The Past 20 Years (December 2004)
Candidates For The Next Generation Of Prostate Cancer Detection Tools (December 2004)
Interpreting The Results Of PSA Testing (March 2004)
Bone Scan Staging Not Recommended When PSA Is < 20 ng/mL (Jan 2004)
The Technetium-99m Radionuclide Bone Scan (December 2003)
Post Therapy PSA Doubling Time Of <3 Months Is A Surrogate For Prostate Cancer Specific Mortality (Nov 2003)
A Nomogram Integrating Variables Affecting Outcome Of Salvage Radiation Therapy Post-Rp (Nov 2003)
Is Occult Cancer in Lymph Nodes the Achilles Heal of Successful treatment? A Few Cells May Cast a Long shadow (October 2003)
Now the World Knows We Need a Better Mousetrap (October 2003)
Percent Of Biopsy Cores That Are Positive Improves Prediction (September 2003)
PAP – Making a Comeback as a Prognostic Indicator (May 2003)
In This Section
